In this week’s podcast, Medtech Insight's managing editor Marion Webb discusses how the US Preventive Services Task Force’s recommendations to lower colon screening to age 45 may impact Exact Sciences’ Cologuard stool test. Deputy editor Reed Miller highlights third-quarter results of Stryker, Boston Science and Edwards Lifesciences.

Listen to the podcast via the player below:

Stryker Sees ‘V-Shape’ Recovery In Third Quarter

Boston Scientific Exceeds Wall Street’s Expectations In Q3

Edwards Returns To Growth In The Third Quarter

USPSTF Recommendations For Colon Cancer Screening At Age 45 Could Give Cologuard A Boost

For more information on Medtech Insight and to start a free trial, click here: http://bit.ly/2w7LnlR

Medtech Insight articles addressing topics discussed in this episode: